Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.
2.

Donor polymorphism of tumor necrosis factor gene: relationship with variable severity of hepatitis C recurrence after liver transplantation.

Rosen HR, Lentz JJ, Rose SL, Rabkin J, Corless CL, Taylor K, Chou S.

Transplantation. 1999 Dec 27;68(12):1898-902.

PMID:
10628771
3.

Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation.

Ben-Ari Z, Pappo O, Druzd T, Sulkes J, Klein T, Samra Z, Gadba R, Tambur AR, Tur-Kaspa R, Mor E.

Cytokine. 2004 Jul 7;27(1):7-14.

PMID:
15207246
4.

Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C virus disease in liver transplantation.

Mas VR, Fisher RA, Maluf DG, Archer KJ, Contos MJ, Mills SA, Shiffman ML, Wilkinson DS, Oliveros L, Garrett CT, Ferreira-Gonzalez A.

Clin Genet. 2004 Mar;65(3):191-201.

PMID:
14756669
5.

Tumor necrosis factor-alpha promoter polymorphisms and the risk of rejection after liver transplantation: a case control analysis of 210 donor-recipient pairs.

Jazrawi SF, Zaman A, Muhammad Z, Rabkin JM, Corless CL, Olyaei A, Biggs A, Ham J, Chou S, Rosen HR.

Liver Transpl. 2003 Apr;9(4):377-82.

6.

Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.

de Arias AE, Haworth SE, Belli LS, Burra P, Pinzello G, Vangeli M, Minola E, Guido M, Boccagni P, De Feo TM, Torelli R, Cardillo M, Scalamogna M, Poli F.

Liver Transpl. 2009 Apr;15(4):390-9. doi: 10.1002/lt.21673.

7.
8.

Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome.

Watt KD, Lyden ER, Gulizia JM, McCashland TM.

Liver Transpl. 2006 Jan;12(1):134-9.

9.

Transforming growth factor β1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus--induced liver disease.

Eurich D, Bahra M, Boas-Knoop S, Lock JF, Golembus J, Neuhaus R, Neuhaus P, Neumann UP.

Liver Transpl. 2011 Mar;17(3):279-88. doi: 10.1002/lt.22190.

10.

Investigation of promoter polymorphisms in the tumor necrosis factor-alpha and interleukin-10 genes in liver transplant patients.

Fernandes H, Koneru B, Fernandes N, Hameed M, Cohen MC, Raveche E, Cohen S.

Transplantation. 2002 Jun 27;73(12):1886-91.

PMID:
12131682
11.

DR antigens influence graft outcome and HCV recurrence after liver transplantation.

Kimball P, Stravitz T.

Transplant Proc. 2005 Mar;37(2):1099-100.

PMID:
15848634
12.

Polymorphisms in tumour necrosis factor alpha, interleukin-10 and transforming growth factor beta1 genes and end-stage liver disease.

Bathgate AJ, Pravica V, Perrey C, Hayes PC, Hutchinson IV.

Eur J Gastroenterol Hepatol. 2000 Dec;12(12):1329-33.

PMID:
11192323
13.

Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients.

Tambur AR, Ortegel JW, Ben-Ari Z, Shabtai E, Klein T, Michowiz R, Tur-Kaspa R, Mor E.

Transplantation. 2001 May 27;71(10):1475-80.

PMID:
11391238
14.

Outcome of living donor liver transplantation for Egyptian patients with hepatitis C (genotype 4)-related cirrhosis.

Yosry A, Esmat G, El-Serafy M, Omar A, Doss W, Said M, Abdel-Bary A, Hosny A, Marawan I, El-Malt O, Kamel RR, Hatata Y, Ghali A, Sabri H, Kamel S, El-Gbaly H, Tanaka K.

Transplant Proc. 2008 Jun;40(5):1481-4. doi: 10.1016/j.transproceed.2008.03.085.

PMID:
18589133
15.

Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury.

Zekry A, Bishop GA, Bowen DG, Gleeson MM, Guney S, Painter DM, McCaughan GW.

Liver Transpl. 2002 Mar;8(3):292-301.

16.

Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients.

Burra P, Loreno M, Russo FP, Germani G, Galligioni A, Senzolo M, Cillo U, Zanus G, Fagiuoli S, Rugge M.

Liver Transpl. 2009 Jun;15(6):619-28. doi: 10.1002/lt.21761.

17.

[Cytokine gene polymorphism in sensitized kidney transplant recipients and its association with acute rejection episodes].

Gu XW, Zhao M, Li LY, Li M, Qian J.

Di Yi Jun Yi Da Xue Xue Bao. 2003 Nov;23(11):1211-3. Chinese.

PMID:
14625191
18.

The effect of polymorphisms in tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in acute hepatic allograft rejection.

Bathgate AJ, Pravica V, Perrey C, Therapondos G, Plevris JN, Hayes PC, Hutchinson IV.

Transplantation. 2000 Apr 15;69(7):1514-7.

PMID:
10798783
19.

Donor-specific hyporesponsiveness in ELISPOT assay is associated with early recurrence of hepatitis C in liver transplant recipients.

Tambur AR, Ben-Ari Z, Herrera ND, Klein T, Michowiz R, Mor E.

Hum Immunol. 2005 Jan;66(1):21-7.

PMID:
15620458
20.

Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis.

Briceño J, Ciria R, Pleguezuelo M, de la Mata M, Muntané J, Naranjo A, Sánchez-Hidalgo J, Marchal T, Rufián S, López-Cillero P.

Liver Transpl. 2009 Jan;15(1):37-48. doi: 10.1002/lt.21566.

Supplemental Content

Support Center